Story preview
With 402,577 common shares, Retension Pharmaceuticals (RTSN) CEO also holds options priced from $1.43.
About this story
- Published
- Oct 14, 2026, 12:14 AM UTC
Topics in this story
Continue reading on the publisher site for the full article.
Read on publisher →Stock Titan
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee